Welcome to our dedicated page for Acurx Pharmaceuticals news (Ticker: ACXP), a resource for investors and traders seeking the latest updates and insights on Acurx Pharmaceuticals stock.
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The ACXP news feed on Stock Titan brings together company press releases, scientific updates and regulatory disclosures that highlight progress across its DNA polymerase IIIC (pol IIIC) inhibitor platform.
Readers can follow detailed announcements on ibezapolstat, Acurx’s lead oral Gram-Positive Selective Spectrum (GPSS®) antibiotic candidate for Clostridioides difficile Infection (CDI). News items include Phase 2 clinical data, preparations for international Phase 3 trials, and regulatory milestones such as FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations, EMA scientific advice, and a positive opinion from the EMA Paediatric Committee on the Pediatric Investigation Plan for ibezapolstat in children.
The ACXP news stream also covers developments in Acurx’s preclinical DNA pol IIIC pipeline, including patents granted in multiple jurisdictions for the ACX-375C program, collaborations with Leiden University Medical Center (LUMC) on structural biology of pol IIIC, and presentations at major scientific meetings like IDWeek and other infectious disease conferences. These updates often describe new data on microbiome selectivity, bile acid profiles, and potential class effects across the company’s inhibitor series.
Investors and observers can track capital markets and corporate actions reported by Acurx, such as warrant inducement transactions, equity line financings, and a 1-for-20 reverse stock split undertaken to support continued Nasdaq listing. For anyone monitoring antibiotic innovation against Gram-positive priority pathogens, the ACXP news page provides an organized view of Acurx’s clinical, regulatory, scientific and financing milestones over time.
Acurx Pharmaceuticals (NASDAQ: ACXP) has announced a 1-for-20 reverse stock split effective August 4, 2025, at 4:01 p.m. ET. The company's stock will begin trading on a split-adjusted basis on August 5, 2025, under the same ticker "ACXP" but with a new CUSIP number (00510M 203).
The reverse split will reduce outstanding shares from approximately 30.7 million to 1.5 million. The move aims to increase the per-share trading price to regain compliance with Nasdaq's minimum bid price requirement. Stockholders will receive cash payments for fractional shares based on the closing price on August 1, 2025.
Proportional adjustments will be made to stock options, warrants, and shares under incentive plans. Most shareholders won't need to take action, as positions will be automatically adjusted through their brokers.
Acurx Pharmaceuticals (NASDAQ: ACXP), a clinical stage biopharmaceutical company focused on developing novel antibiotics for difficult-to-treat bacterial infections, has scheduled its Q2 2025 financial results conference call for August 12, 2025, at 8:00 AM ET. The company's leadership team, including CEO David P. Luci and CFO Robert G. Shawah, will host the call to discuss quarterly results and provide a business update.
Investors can access the call toll-free from the U.S. at 1-877-790-1503 using Conference ID: 13755161, with international dial-in numbers available through the company's conferencing system.
Acurx Pharmaceuticals (NASDAQ: ACXP) reported its Q1 2025 financial results and business updates. The company raised $3.6 million through two registered direct offerings and secured a $12 million equity line of credit. Q1 financial highlights include a net loss of $2.1 million ($0.11 per share), improved from a $4.4 million loss year-over-year, with reduced R&D expenses of $0.6 million and G&A expenses of $1.6 million.
Key developments include positive EMA guidance for ibezapolstat's Phase 3 clinical trial program, aligned with FDA requirements. Two significant studies funded by NIAID demonstrated ibezapolstat's microbiome-restorative potential and favorable gut microbiome impact compared to other antibiotics. The company also secured new patents in Japan and India for DNA polymerase IIIC inhibitors, extending protection until December 2039.
Acurx Pharmaceuticals (NASDAQ: ACXP), a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult-to-treat bacterial infections, has scheduled its first quarter 2025 financial results conference call for May 13, 2025, at 8:00 am ET.
The conference call will be led by David P. Luci, President and CEO, and Robert G. Shawah, Chief Financial Officer. They will present the financial results and provide a business update before the U.S. markets open.
Interested participants can join the call using the following details:
- U.S. Toll-free: 1-877-790-1503
- Conference ID: 13753625
- International callers can access toll-free numbers via a dedicated website
Acurx Pharmaceuticals (Nasdaq: ACXP) has announced its participation in the Alliance Global Partners (A.G.P) Healthcare Company Showcase on May 21, 2025, at 9:00 a.m. ET. David P. Luci, President & CEO, will engage in a virtual fireside chat presentation.
The company, which specializes in developing small molecule antibiotics for difficult-to-treat bacterial infections, will showcase its lead antibiotic candidate ibezapolstat (IBZ). This drug is prepared to progress to international Phase 3 clinical trials for treating C. difficile infection (CDI).
The presentation will be available via live webcast, with a replay accessible through the News/Events section on the company's website at www.acurxpharma.com.
Acurx Pharmaceuticals (NASDAQ: ACXP) has been granted a new patent by the Indian Patent Office in March 2025 for DNA Polymerase IIIC Inhibitors, including compositions-of-matter. This adds to their existing portfolio of three U.S. patents, one Israeli patent, and one Japanese patent, all covering the ACX-375C program.
The company's lead DNA pol IIIC inhibitor is Phase 3-ready for oral treatment of C. difficile Infection. Their second-generation compounds are being developed for both oral and parenteral use to treat infections caused by gram-positive bacteria, including:
- Staphylococcus aureus (including MRSA)
- VRE and DRSP
- B. anthracis (anthrax), a Bioterrorism Category A Threat-Level pathogen
FAQ
What is the current stock price of Acurx Pharmaceuticals (ACXP)?
What is the market cap of Acurx Pharmaceuticals (ACXP)?
